Atea Pharma Files Q1 2025 10-Q, Notes Merck Deal
Ticker: AVIR · Form: 10-Q · Filed: May 12, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, licensing-agreement, subsequent-event
Related Tickers: MRK
TL;DR
Atea Pharma Q1 10-Q out. Merck deal happened post-period. Check financials.
AI Summary
Atea Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operations, including information related to the Merck License Agreement which occurred between April 1, 2025, and April 30, 2025. The company's fiscal year ends on December 31st.
Why It Matters
This filing provides investors with an update on Atea Pharmaceuticals' financial health and operational activities for the first quarter of 2025, including significant post-period events like the Merck License Agreement.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the nature of pharmaceutical development and licensing agreements introduces inherent risks.
Key Numbers
- Q1 2025 — Reporting Period (The financial and operational data covers the first quarter of 2025.)
- March 31, 2025 — Period End Date (The 10-Q report is for the period ending on this date.)
- May 12, 2025 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- Merck License Agreement (company) — Subsequent event mentioned in the filing
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- 2025-04-01 (date) — Start date of the Merck License Agreement period
- 2025-04-30 (date) — End date of the Merck License Agreement period
FAQ
What is the specific nature of the Merck License Agreement mentioned as a subsequent event?
The filing mentions the 'Merck License Agreement' as a subsequent event occurring between April 1, 2025, and April 30, 2025, but does not provide specific details within the provided text.
What were Atea Pharmaceuticals' key financial results for the quarter ending March 31, 2025?
The provided text is a header and does not contain specific financial results for the quarter ending March 31, 2025.
What is Atea Pharmaceuticals' primary business sector?
Atea Pharmaceuticals, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' sector, with SIC code 2834.
When does Atea Pharmaceuticals' fiscal year end?
Atea Pharmaceuticals' fiscal year ends on December 31st.
What is the SEC file number for Atea Pharmaceuticals?
The SEC file number for Atea Pharmaceuticals is 001-39661.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).